Will assess all patients who present with a need for joint replacement arthroplasty to determine whether disease state is indicated for partial, Bicruciate retaining, or total knee replacement. These patients will be treated according to surgeon preference at each center. Only minimal information on this data set will be collected.
Patients who receive the cemented Vanguard XP BiCruciate Knee System based on meeting indications for use, and inclusion / exclusion criteria described in the protocol.
Subjects will be considered to be included in this trial if they satisfy all of the following criteria:
Meet the FDA cleared indications for use:
Painful and disabled knee joint resulting from osteoarthritis, rheumatoid arthritis or traumatic arthritis where one or more compartments are involved.
Correction of varus, valgus, or posttraumatic deformity
Correction or revision of unsuccessful osteotomy, arthrodesis, or failure of a previous joint replacement procedure.
The FDA has cleared the following components as indicated, but for purposes of this study we will only include cemented component fixation to limit variables:
Femoral components and tibial tray components with porous coatings are indicated for cemented and uncemented biological fixation application. Non-coated (Interlok®) devices and all polyethylene patellar components are indicated for cemented application only. Regenerex components are intended for uncemented biologic fixation application.